Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05206513 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
A Phase 3 study of Cerebral Palsy and Dyskinesia, sponsored by Neurocrine Biosciences.
- Active
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
- 20
- Study locations
NCT05206513: Active Phase 3 study of Cerebral Palsy and Dyskinesia, sponsored by Neurocrine Biosciences.
NCT05206513 is a Phase 3 study of Cerebral Palsy and Dyskinesia that is active but no longer recruiting, run by Neurocrine Biosciences. The registered enrollment target is 86 participants, below the 228-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05206513, a Phase 3 study of Cerebral Palsy and Dyskinesia, is active but no longer recruiting, sponsored by Neurocrine Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Valbenazine
Study Locations (20)
Florida
- Neurocrine Clinical Site - Gulf Breeze
- Neurocrine Clinical Site - Miami
- Neurocrine Clinical Site - Orlando
Texas
- Neurocrine Clinical Site - Dallas
- Neurocrine Clinical Site - Fort Worth
- Neurocrine Clinical Site - Houston
Ohio
- Neurocrine Clinical Site - Cincinnati
- Neurocrine Clinical Site - Columbus
California
- Neurocrine Clinical Site - San Diego
Colorado
- Neurocrine Clinical Site - Aurora
Connecticut
- Neurocrine Clinical Site - Stamford
Illinois
- Neurocrine Clinical Site - Chicago
Maryland
- Neurocrine Clinical Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
What the registry record for NCT05206513 still lists
NCT05206513 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 228-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Cerebral Palsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05206513 names 20 study sites across 15 states, led by Florida, Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT05206513 about?
NCT05206513 is a clinical study titled "Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy". The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.
What is the current status of trial NCT05206513?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2022-04-15. Estimated completion is 2026-06.
What conditions does trial NCT05206513 study?
This clinical trial studies the following conditions: Cerebral Palsy, Dyskinesia.
What interventions are being tested in trial NCT05206513?
The interventions under investigation include: Placebo (DRUG), Valbenazine (DRUG).
Who is sponsoring clinical trial NCT05206513?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05206513 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Palsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05206513's enrollment target sits among peer trials
86 25th of 91 higher than 67 of 91 other Cerebral Palsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cerebral Palsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
COMPLETED · Phase 3
-
Stand-on Ride-on Power Mobility Devices for Children With Cerebral Palsy
RECRUITING · Early Phase 1
-
Motor Training for Infants With Cerebral Palsy
RECRUITING · NA
-
Implementation of Therapy Together
RECRUITING · NA
-
Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
RECRUITING · NA
-
Em-power: Maximizing Functional Independence for Children With Severe Cerebral Palsy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI